ERK1/2 anticorps
-
- Antigène Voir toutes ERK1/2 (MAPK1/3) Anticorps
- ERK1/2 (MAPK1/3) (Mitogen-Activated Protein Kinase 1/3 (MAPK1/3))
-
Reactivité
- Humain, Souris
-
Hôte
- Souris
-
Clonalité
- Monoclonal
-
Conjugué
- Cet anticorp ERK1/2 est non-conjugé
-
Application
- Western Blotting (WB), ELISA, Immunohistochemistry (IHC), Flow Cytometry (FACS)
- Purification
- purified
- Immunogène
- Purified recombinant fragment of human MAPK expressed in E. coli.
- Clone
- 3F8
- Isotype
- IgG2b
- Top Product
- Discover our top product MAPK1/3 Anticorps primaire
-
-
- Indications d'application
- ELISA: 1:10000, WB: 1:500 - 1:2000, IHC: 1:200 - 1:1000, FCM: 1:200 - 1:400
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Buffer
- Ascitic fluid containing 0.03 % sodium azide.
- Agent conservateur
- Sodium azide
- Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Stock
- 4 °C/-20 °C
- Stockage commentaire
- 4°C, -20°C for long term storage
-
-
Protein kinase Cdelta supports survival of MDA-MB-231 breast cancer cells by suppressing the ERK1/2 pathway." dans: The Journal of biological chemistry, Vol. 284, Issue 48, pp. 33456-65, (2009) (PubMed).
: "
-
Protein kinase Cdelta supports survival of MDA-MB-231 breast cancer cells by suppressing the ERK1/2 pathway." dans: The Journal of biological chemistry, Vol. 284, Issue 48, pp. 33456-65, (2009) (PubMed).
-
- Antigène
- ERK1/2 (MAPK1/3) (Mitogen-Activated Protein Kinase 1/3 (MAPK1/3))
- Autre désignation
- p44/42 MAPK (Erk1/2) (MAPK1/3 Produits)
- Synonymes
- anticorps erk1/2, anticorps mitogen-activated protein kinase, anticorps erk1/2
- Sujet
-
Description: Mitogen-activated protein kinases (MAPKs) are a widely conserved family of serine/threonine protein kinases involved in many cellular programs such as cell proliferation, differentiation, motility, and death. The p44/42 MAPK (Erk1/2) signaling pathway can be activated in response to a diverse range of extracellular stimuli including mitogens, growth factors, and cytokines and is an important target in the diagnosis and treatment of cancer. Upon stimulation, a sequential three-part protein kinase cascade is initiated, consisting of a MAP kinase kinase kinase (MAPKKK or MAP3K), a MAP kinase kinase (MAPKK or MAP2K), and a MAP kinase (MAPK). Multiple p44/42 MAP3Ks have been identified, including members of the Raf family as well as Mos and Tpl2/Cot. MEK1 and MEK2 are the primary MAPKKs in this pathway. MEK1 and MEK2 activate p44 and p42 through phosphorylation of activation loop residues Thr202/Tyr204 and Thr185/Tyr187, respectively. Several downstream targets of p44/42 have been identified, including p90RSK and the transcription factor Elk-1. p44/42 are negatively regulated by a family of dual-specificity (Thr/Tyr) MAPK phosphatases, known as DUSPs or MKPs, along with MEK inhibitors such as U0126 and PD98059.
Aliases: ERK, p38, p40, p41, ERK2, ERT1, MAPK2, PRKM1, PRKM2, P42MAPK, p41mapk, MAPK1
- Poids moléculaire
- 42 kDa
- ID gène
- 5594
- HGNC
- 5594
-